All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubGVhD HubLymphoma HubMDS HubMPN HubMultiple Myeloma
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert Opinions

ASH 2020: Highlights for patients with TP53-mutated AML

By Natasha Fort
Featured
Uwe Platzbecker
Jan 20, 2021
Share:

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, about the highlights for patients with TP53-mutated AML from ASH 2020.

ASH 2020: Highlights for patients with TP53-mutated AML

Platzbecker highlights the findings from a study evaluating the combination of azacitidine and magrolimab in patients with AML, including TP53-mutant AML.

Share:
More about...
AML-related mutationsASH 2020AzacitidineMagrolimabTP53

Related articles

Newsletter

Subscribe to get the best content related to AML delivered to your inbox